Peter Lloyd

Special issue: Values in the design process: Editorial

Janet McDonnell, Peter Lloyd, 2009 .

Clinical Pharmacokinetics of Imatinib

Peter Lloyd, B. Peng, H. Schran, 2005, Clinical pharmacokinetics.

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.

Peter Lloyd, Jennifer Sims, Patrick Y Muller, 2009, Current opinion in biotechnology.